X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs CIPLA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA CIPLA ABBOTT INDIA/
CIPLA
 
P/E (TTM) x 43.1 44.6 96.7% View Chart
P/BV x 10.8 3.8 281.7% View Chart
Dividend Yield % 0.6 0.3 185.6%  

Financials

 ABBOTT INDIA   CIPLA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
CIPLA
Mar-17
ABBOTT INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs6,015622 967.2%   
Low Rs3,707458 808.9%   
Sales per share (Unadj.) Rs1,236.9181.9 680.2%  
Earnings per share (Unadj.) Rs122.212.9 949.3%  
Cash flow per share (Unadj.) Rs129.029.3 440.0%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %0.70.4 194.4%  
Book value per share (Unadj.) Rs521.2155.7 334.8%  
Shares outstanding (eoy) m21.25804.51 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.93.0 132.3%   
Avg P/E ratio x39.842.0 94.8%  
P/CF ratio (eoy) x37.718.4 204.6%  
Price / Book Value ratio x9.33.5 268.8%  
Dividend payout %28.615.5 184.3%   
Avg Mkt Cap Rs m103,296434,516 23.8%   
No. of employees `0003.023.0 12.8%   
Total wages/salary Rs m3,37026,338 12.8%   
Avg. sales/employee Rs Th8,891.86,349.1 140.0%   
Avg. wages/employee Rs Th1,140.01,143.0 99.7%   
Avg. net profit/employee Rs Th878.3449.3 195.5%   
INCOME DATA
Net Sales Rs m26,284146,302 18.0%  
Other income Rs m5042,287 22.1%   
Total revenues Rs m26,789148,589 18.0%   
Gross profit Rs m3,66524,758 14.8%  
Depreciation Rs m14413,229 1.1%   
Interest Rs m81,594 0.5%   
Profit before tax Rs m4,01712,222 32.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4211,798 79.0%   
Profit after tax Rs m2,59610,354 25.1%  
Gross profit margin %13.916.9 82.4%  
Effective tax rate %35.414.7 240.5%   
Net profit margin %9.97.1 139.6%  
BALANCE SHEET DATA
Current assets Rs m14,44687,370 16.5%   
Current liabilities Rs m4,72533,081 14.3%   
Net working cap to sales %37.037.1 99.7%  
Current ratio x3.12.6 115.8%  
Inventory Days Days5187 59.1%  
Debtors Days Days2062 31.4%  
Net fixed assets Rs m1,113111,567 1.0%   
Share capital Rs m2131,609 13.2%   
"Free" reserves Rs m10,808123,645 8.7%   
Net worth Rs m11,076125,254 8.8%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m16,241209,532 7.8%  
Interest coverage x497.08.7 5,733.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.60.7 231.8%   
Return on assets %16.05.7 281.2%  
Return on equity %23.48.3 283.6%  
Return on capital %36.38.5 427.5%  
Exports to sales %0.634.2 1.8%   
Imports to sales %12.68.3 151.6%   
Exports (fob) Rs m16250,050 0.3%   
Imports (cif) Rs m3,32212,203 27.2%   
Fx inflow Rs m26851,066 0.5%   
Fx outflow Rs m3,92717,678 22.2%   
Net fx Rs m-3,65933,388 -11.0%   
CASH FLOW
From Operations Rs m2,51423,824 10.6%  
From Investments Rs m-800-13,127 6.1%  
From Financial Activity Rs m-803-13,239 6.1%  
Net Cashflow Rs m912-2,478 -36.8%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 7.9 12.2 64.8%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.1 26.2 65.3%  
Shareholders   18,270 161,166 11.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  SUVEN LIFE  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Metal Stocks Top Losers(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading marginally above the dotted line.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 21, 2018 03:33 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - J.B.CHEMICALS COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS